- Home
- ABBV
ABBV
AbbVie Inc.
as of 02-27-2026 3:35pm EST
$230.89
+$6.19
+2.76%
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 400.9B | IPO Year: | 2012 |
| Target Price: | $247.06 | AVG Volume (30 days): | 6.0M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 2.36 | EPS Growth: | -1.26 |
| 52 Week Low/High: | $164.39 - $244.81 | Next Earning Date: | 04-13-2026 |
| Revenue: | $61,160,000,000 | Revenue Growth: | 8.57% |
| Revenue Growth (this year): | 11.9% | Revenue Growth (next year): | 8.44% |
| P/E Ratio: | 94.81 | Index: | |
| Free Cash Flow: | 17.8B | FCF Growth: | -0.09% |
AI-Powered ABBV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 74.84%
74.84%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
Siatis Perry C
Sell
EVP, GC AND SECRETARY
ABBV Feb 25, 2026
Avg Cost/Share
$230.00
Shares
22,381
Total Value
$5,147,630.00
Owned After
38,137
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 25, 2026 | Sell | $230.00 | 22,381 | $5,147,630.00 | 38,137 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Zacks
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks
📉
AI Sentiment
Negative
3/10
Simply Wall St.
AbbVie’s CLL Breakthrough And US$380m Build Out Test Valuation
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears
📈
AI Sentiment
Highly Positive
8/10
MarketBeat
Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
AbbVie Could See Continued Outperformance Despite Market Concerns, RBC Capital Markets Says
📊
AI Sentiment
Positive
7/10
Compare ABBV vs Leading Stocks
See how ABBV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.